• Selection of Plasmodium Falciparum pfcrt and pfmdr1 Polymorphisms After Treatment with Artesunate-Amodiaquine Fixed Dose Combination or Artemether-Lumefantrine in Liberia

      Otienoburu, SD; Maïga-Ascofaré, O; Schramm, B; Jullien, V; Jones, JJ; Zolia, YM; Houzé, P; Ashley, EA; Kiechel, JR; Guérin, PJ; et al. (BioMed Central (Springer Science), 2016-09-05)
      Plasmodium falciparum uncomplicated malaria can successfully be treated with an artemisinin-based combination therapy (ACT). However resistance is spreading to the different ACT compounds; the artemisinin derivative and the partner drug. Studies of P. falciparum polymorphisms associated with drug resistance can provide a useful tool to track resistance and guide treatment policy as well as an in-depth understanding of the development and spread of resistance.
    • A Worldwide Map of Plasmodium Falciparum K13-Propeller Polymorphisms

      Ménard, D; Khim, N; Beghain, J; Adegnika, AA; Shafiul-Alam, M; Amodu, O; Rahim-Awab, G; Barnadas, C; Berry, A; Boum, Y; et al. (Massachusetts Medical Society, 2016-06-23)
      Recent gains in reducing the global burden of malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domains are the major determinant of resistance has provided opportunities for monitoring such resistance on a global scale.